What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
The Motley Fool
JANUARY 14, 2024
Now that it has an approved treatment in Casgevy, there's undoubtedly going to be more of a spotlight on the company. Here's why CRISPR could be an attractive acquisition target, and what it would mean for investors if the company is bought out this year. The company will share in the profits on Casgevy with Vertex.
Let's personalize your content